首頁 > 市場調查報告書 > 製藥

癌症分子標靶治療學

市場調查報告書

商品編碼

1838093

OX40標靶治療藥的臨床試驗，治療方法，專利技術平台，市場機會(2026年)

OX40 Targeted Therapies Clinical Trials, Therapeutic Approaches, Proprietary Technology Platforms & Market Opportunity Insight 2026

出版日期: 2025年10月01日 | 出版商:

KuicK Research | 英文 100 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

OX40標靶療法：臨床試驗、治療方法、專有技術平台和市場機會 (2026) 報告結果和亮點

首個OX40標靶療法將於2030年獲批
正在進行臨床試驗的OX40標靶療法：超過10種療法
癌症在OX40標靶療法臨床試驗領域佔主導地位
OX40標靶療法臨床試驗洞察（按公司、國家、適應症和階段劃分）
OX40標靶療法專有技術（依公司分法）
競爭格局

OX40/OX40L標靶療法的需求及其重要性本報告摘要

OX40/OX40L標靶療法作為下一代免疫調節的新靶點，正迅速受到廣泛關注，尤其是在免疫介導疾病（如異位性皮膚炎、氣喘和其他發炎性疾病）中。本報告概述了這個快速發展的領域，製藥投資和學術興趣正在匯聚，創造出一個充滿活力的候選化合物研發管線。

隨著多個候選藥物進入後期臨床試驗階段，以及技術創新從診斷配對擴展到聯合策略，了解OX40/OX40L療法的前景和未來方向變得前所未有的重要。本報告旨在讓包括投資者、生物技術高管和臨床研究人員在內的行業參與者了解這一治療方向不斷發展的潛力及其驅動因素。

本報告關於 OX40/OX40L 標靶療法臨床試驗的見解

OX40/OX40L 療法的臨床發展勢頭強勁，多個候選藥物正在研發中。尤其值得注意的是，臨床試驗在發炎性皮膚病治療中顯示出良好的療效。重要的是，這些療法展現出持久療效和選擇性免疫調節的潛力，這些特點使其有別於現有的標準治療。在美國以外，歐洲、中國和澳洲臨床活動的不斷拓展顯示全球對這些免疫療法的興趣日益濃厚。這種地理擴張標誌著全球市場對這些療法的廣泛認可，並可能為未來的監管批准鋪平道路。

技術平台、合作夥伴關係和協定

本報告重點介紹的創新技術之一是 autoRx40 平台，這是一個針對 OX40 和其他相關免疫受體的專有療法開發引擎。該技術結合了抗體工程和分子設計能力，可以快速開發雙特異性和多特異性抗體。 autoRx40 的模組化設計和設計使其能夠提供標靶治療，將免疫抑制和致病性免疫細胞耗竭效應相結合。候選藥物 HX035 和 HX038 是此技術在複雜自體免疫疾病治療的應用範例。該平台反映了業界正在朝著開發可擴展且靈活的治療引擎的方向發展，以滿足不斷變化的臨床需求。

積極參與 OX40/OX40L 標靶療法研發的主要公司

大型製藥和生技公司也在角逐 OX40/OX40L 療法領域。賽諾菲和安進正在完善具有重磅潛力的後期候選藥物，而像 Astria Therapeutics 這樣的新進入者則透過創新的工程改進展示了有希望的早期證據。像 ImageneBio 這樣的公司也致力於利用成熟的抗體技術來提高安全性並最大限度地減少脫靶效應。

這些進展通常由合資企業、策略聯盟和學術合作推動，它們推動創新週期並加快臨床進展。隨著這些療法的進一步發展，患者反應、安全性和差異化的給藥間隔可能成為市場成功的指標。

報告顯示OX40/OX40L標靶療法的未來發展

OX40/OX40L療法正根據疾病嚴重程度和患者特徵從單一療法發展為聯合療法。未來，可能會出現將生物製劑與精準診斷結合以優化治療效果的策略。具有長半衰期、低免疫原性且患者依從性良好的治療藥物正在開發中，這對現有療法構成了巨大挑戰。隨著後期數據的累積和監管障礙的消除，這些療法有可能為免疫疾病治療樹立新的標準。本文為有興趣了解和投資未來免疫學創新浪潮的利害關係人提出了策略願景。

First OX40 Targeted Therapy Approval By 2030
OX40 Targeted Therapies In Clinical Trials: > 10 Therapies
Cancer Dominating OX40 Targeted Therapies Clinical Trials Landscape
OX40 Targeted Therapies Clinical Trials Insight By Company, Country, Indication & Phase
OX40 Targeted Therapies Proprietary Technologies By Company
Competitive Landscape

Need For OX40/OX40L Targeted Therapies & Why This Report

OX40/OX40L targeted therapies are rapidly becoming the new target for next generation immunomodulation, especially in immune mediated disorders like atopic dermatitis, asthma, and other inflammatory conditions. This report gives an overview of this fast evolving space, where pharmaceutical investment and academia interest are merging to bring forth a vibrant pipeline of contenders.

With several candidates in late stage trials and innovation extending into combination strategies as well as diagnostic pairing, knowing the landscape and future direction of OX40/OX40L therapies has never been more important. The report is intended to educate industry players, including investors, biotech executives, and clinical researchers, on the evolving potential of this therapeutic axis and the drivers making it happen

OX40/OX40L Targeted Therapies Clinical Trials Insight Covered In Report

Clinical momentum for OX40/OX40L therapies is increasing, with multiple candidates moving through the pipeline. Particular note has been made of trials indicating promising results in inflammatory dermatological diseases, in which patients tend to have limited alternatives and relapsing disease. Significantly, these treatments are also exhibiting potential for durability of response and selective immune modulation, characteristics that set them apart from existing standards of care. Outside of the US, expanded clinical activity in Europe, China, and Australia demonstrates an expanding global interest in these immunotherapies. This geographical expansion indicates broader acceptance and future potential for regulatory paths across global markets.

Technology Platforms, Partnerships & Agreements

One of the innovations noted in this report is the autoRx40 Platform, which is a proprietary therapeutic development engine that targets OX40 and other related immune receptors. The technology combines antibody engineering and molecular design capabilities to quickly develop bispecific and multi-specific antibodies. Its modular nature and modularity of design enable autoRx40 to deliver targeted therapies that are both immune inhibiting and depleting pathogenic immune cells. The use of the technology in the treatment of complex autoimmune diseases is exemplified through candidates HX035 and HX038. The platform reflects a larger movement in the industry towards the development of scalable and flexible therapeutic engines to address the changing clinical needs.

Leading Companies Active In R&D On OX40/OX40L Targeted Therapies

Several drug making giants and biotech disruptors are making bets in the OX40/OX40L therapy arena. Sanofi and Amgen are taking late-stage candidates with blockbuster potential to the finish, while more recent entrants like Astria Therapeutics are showing promising early-stage evidence with innovative engineering improvements. Companies like ImageneBio are also targeting enhanced safety and minimized off-target effects via matured antibody technologies.

These advancements are frequently fostered by joint ventures, strategic alliances, and academic collaborations that drive innovation cycles and facilitate clinical progress. With further development of these therapies, differentiation among patient response, safety profiles, and dosing intervals will be the marker for success in the marketplace.

Report Indicating Future Development Of OX40/OX40L Targeted Therapies

OX40/OX40L therapies are progressing beyond monotherapy to combinations based on disease severity and patient profile. The future will probably witness combined strategies that bring together biologics and precision diagnostics to optimize therapeutic effects. Future contenders are being developed for longer half-life, less immunogenicity, and better patient compliance, making them strong challengers to current treatments. With late-stage data accumulated and regulatory hurdles cleared, these therapies have the potential to set new standards in immune disease therapy. This paper presents the strategic vision to stakeholders interested in learning or investing in the future wave of immunology innovation.

1. Introduction To OX40/OX40L Pathway

1.1 Background Of OX40/OX40L Pathway
1.2 Significance In Immunotherapy
1.3 OX40/OX40L As Disease Biomarkers

2. Targeting The OX40/OX40L Pathway In Therapy

2.1 OX40/OX40L Agonism
2.2 OX40/OX40L Antagonism
2.3 Targeting Approaches & Mechanisms Of Action
- 2.3.1 Antibodies
- 2.3.2 Nucleic Acids
- 2.3.3 Fusion Protein
- 2.3.4 Small Molecules
- 2.3.5 Peptides

3. Indications For OX40/OX40L Targeted Therapies

3.1 Cancer
- 3.1.1 Solid Tumors
- 3.1.2 Hematologic Malignancies
3.2 Infectious Diseases
3.3 Autoimmune & Inflammatory Diseases
3.4 Other Potential Indications

4. OX40/OX40L Targeted Combination Therapies

5. Global OX40/OX40L Targeted Therapy Clinical Trials Overview

5.1 By Phase
5.2 By Indication
5.3 By Company

6. Global OX40/OX40L Targeted Therapy Clinical Trials Insight By Company, Country, Indication & Phase

6.1 Preclinical
6.2 Phase 0
6.3 Phase I
6.4 Phase I/II
6.5 Phase II
6.6 Phase II/III
6.7 Phase III

7. OX40/OX40L Targeted Therapy Development Platforms By Company

8. Global OX40/OX40L Targeted Therapy Market Outlook

8.1 Current Market Overview
8.2 Future Prospects

9. Global OX40/OX40L Targeted Therapy Market Dynamics

9.1 Growth Drivers & Opportunities
9.2 Challenges & Strategic Solutions

10. Competitive Landscape

10.1 AbCellera Biologics
10.2 Apogee Therapeutics
10.3 Amgen
10.4 Astria Therapeutics
10.5 Bio-Thera
10.6 Elpiscience
10.7 HiFiBiO Therapeutics
10.8 Inhibrx Biosciences
10.9 ImageneBio
10.10 Kyowa Kirin
10.11 Navigator Medicines
10.12 Pfizer
10.13 Psivant Therapeutics
10.14 Sanofi
10.15 Shanghai Henlius Biotech

簡介目錄圖表

List of Figures

Figure 1-1: OX40/OX40L Pathway
Figure 1-2: OX40 In T Cell Subset Differentiation
Figure 1-3: OX40/OX40L Signaling Pathway In Disease
Figure 2-1: OX40 Agonism - Mechanism Of Action On T Cells
Figure 2-2: OX40 Agonism - Potential For Immunotherapy Across Diseases
Figure 2-3: OX40 Antagonism - Mechanism Of Action
Figure 2-4: Types Of OX40 Targeting Antibodies
Figure 2-5: Nanobodies Targeting OX40 - A Novel Approach
Figure 2-6: Nucleic Acid-Based Therapies Targeting OX40/OX40L
Figure 2-7: Fusion Proteins Targeting OX40/OX40L - Advantages
Figure 2-8: Small Molecules Targeting OX40-OX40L - Mechanism Of Action
Figure 2-9: Bicycle Peptides Targeting OX40 - Mechanism Of Action
Figure 3-1: HexAgon-HN Phase 2/3 (NCT06295731) Study - Initiation & Completion Year
Figure 3-2: BAT-6026-001-CR Phase 1 (NCT05105971) Study - Initiation & Completion Year
Figure 3-3: HFB-301001-01 Phase 1 (NCT05229601) Study - Initiation & Completion Year
Figure 3-4: FT04CARCIK Phase 1/2 (NCT05869279) Study - Initiation & Completion Year
Figure 3-5: LY007C1101 Phase 1 (NCT06364852) Study - Initiation & Completion Year
Figure 3-6: HLX51-FIH101 Phase 1 (NCT05788107) Study - Initiation & Completion Year
Figure 3-7: ROCKET-ASCEND Phase 3 (NCT05882877) Study - Initiation & Completion Year
Figure 3-8: ROCKET-Outpost Phase 3 (NCT06224192) Study - Initiation & Completion Year
Figure 3-9: RIVER-AD Phase 2/3 (NCT05492578) Study - Initiation & Completion Year
Figure 3-10: HLX51-FIH101 Phase 1 (NCT05788107) Study - Initiation & Completion Year
Figure 5-1: Global- OX40/OX40L Targeted Therapies In Clinical Trials By Phase, 2025 -2026
Figure 5-2: Global- OX40/OX40L Targeted Therapies In Clinical Trials By Indication, 2025 - 2026
Figure 5-3: Global - OX40/OX40L Targeted Therapies In Clinical Trials By Company, 2025 - 2026
Figure 7-1: ADAPTIR Bispecific
Figure 7-2: ADAPTIR - APVO603
Figure 7-3: Genmab - HexaBody
Figure 7-4: Inhibrx - sdAb Features
Figure 7-5: Conventional vs. sdAb Structure
Figure 7-6: INBRX-106 - Features
Figure 8-1: Global OX40/OX40L Targeting Therapy Market - Future Prospects
Figure 9-1: Global OX40/OX40L Targeting Therapy Market - Drivers & Opportunities
Figure 9-2: Global OX40/OX40L Targeting Therapy Market - Challenges & Strategic Solutions